Research programme: ITK inhibitors - Corvus Pharmaceuticals

Drug Profile

Research programme: ITK inhibitors - Corvus Pharmaceuticals

Alternative Names: CPI-596; CPX-016; Interleukin-2 inducible kinase inhibitor; ITK Inhibitor; T Cell Reprogramming Drug; T-Cell Reprograming Drug

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corvus Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 May 2018 Corvus Pharmaceuticals intends to file an IND application for CPI 596 in late 2018
  • 08 May 2018 Corvus Pharmaceuticals plans a phase I trial for an ITK inhibitor for Cancer in USA in early 2019
  • 26 Apr 2018 Corvus Pharmaceuticals plans a phase I/Ib trial for CPX 006 as single agent and in combination with CPI 444 for Cancer (Second-line therapy or greater) in USA in the March 2018 (NCT03454451)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top